This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Analyzing Iovance's lifileucel Compared to Instil Bio’s main candidate, ITIL-168, in Melanoma

Ticker(s): IOVA, TIL

Who's the expert?

An oncologist/ dermatologist with experience in treating Melanoma.

Interview Questions

Please tell us about your clinical experience. How many patients with melanoma do you see, yearly?

Added By: slingshot_insights

What treatment has seen the best results and why? How could lifileucel or ITIL-168 fit in this space?

Added By: slingshot_insights

Can you tell us more about the field of tumor-infiltrating lymphocytes in cancer cell therapy, considering the oldest successful treatment using this method dates to 1988?

Added By: slingshot_insights

Can we talk about Instill’s results between 2011-2019, where,according to the IPO filing, of the 21 patients treated under compassionate use, 4 showed complete remission of their cancers. Partial remission was observed in 10. Instil said that four patients reported stable disease. A total of 10 patients have since died from complications that arose as their disease progressed.

Added By: slingshot_insights

Instil Bio says that the challenge of manufacturing TIL therapy has limited its use. Where do you see a potential breakthrough in this area, considering that Instil will spend $150m to develop its proprietary process to cryopreserve surgically removed tissue at a regional hub close to a clinical site, shipping samples to one of two Instil manufacturing sites, in Manchester and Los Angeles.

Added By: slingshot_insights

What can you tell us about Iovance’s Gen2 TIL expansion protocol, as it relates to the manufacturing ? In one of its abstracts, the company cites the process to last 22-days.

Added By: slingshot_insights

How likely would you be to switch your patients to either of those 2 therapies, in the future. Which one would you be inclined to use more, and why?

Added By: slingshot_insights

In a meta-analysis of TIL therapies between 1988-2016, data shows an ORR of 41% and a CR rate of 12% in 410 heavily pretreated patients with metastatic melanoma, withone of 28 patients experiencing disease recurrence. How does this compare to standard of care?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.